SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Vion (formerly Oncorx) interesting play on Gene Therapy
An SI Board Since April 1996
Posts SubjectMarks Bans Symbol
370 14 0 VION
Emcee:  Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
345OUCH:Vion Suspends Phase III Trial Of Drug For Relapsed AML >VION DOW JONES Jim Oravetz-5/23/2007
344Another strong close today. Trading AH at high of day $2. Vol stronger than usHal-4/26/2007
343VION hit a 52-week high today, closing at 2.01 on 3.1 million shares.Sr K-4/23/2007
342Does anyone have any comments on new convertible bond issue? This seems very odbuffalodon2003-2/14/2007
341As many are probably aware, VION announced today that they went to their 2nd stabuffalodon2003-1/25/2007
340Does anyone know of reason for jump in stock today? The volume chart seems to ibuffalodon2003-11/17/2006
339Vion Pharmaceuticals Reaches Midpoint of Patient Accrual to Cloretazine(R) (VNP4Jim Oravetz-11/13/2006
338Vion Pharm 3Q Loss Widens On 63% Increase In Costs >VION DOW JONES NEWSWIRES Jim Oravetz-11/9/2006
337While Cloretazine had lots of promise, there is still lots of time and $$$ needeJim Oravetz-10/30/2006
336I think they may be on to something here, but anything with experimental drugs haladin-10/27/2006
335Vion: Cloretazine Active As Single Agent In Solid Tumor DOW JONES NEWSWIRES OctJim Oravetz-10/27/2006
334Vion Pharmaceuticals 2Q Losses 10c/Shr Vs 8c/Shr >VION August 8, 2006 6:12 p.Jim Oravetz-8/10/2006
333Vion Presents Preclinical Data on Cloretazine(R) (VNP40101M), a Hypoxia-SelectivJim Oravetz-4/4/2006
332I thought you may have missed some zeros in the revenue numbers, but you had it Sr K-3/1/2006
331Vion Pharma 4Q Loss Narrows To $4.7M From $5.2M DOW JONES NEWSWIRES February 28,Jim Oravetz-3/1/2006
330Vion Pharmaceuticals Announces Plans to Conduct a Pivotal Phase II Trial of ClorJim Oravetz-3/1/2006
329Vion Gets FDA Fast Track For Anti-Cancer Cloretazine DOW JONES NEWSWIRES OctoberJim Oravetz-10/17/2005
328Vion Initiates Phase II Trial Of Cloretazine(R) In Small Cell Lung Cancer DOW JOJim Oravetz-9/20/2005
327Vion Pharma 2Q Losses 8c/Shr Vs 7c DOW JONES NEWSWIRES August 5, 2005 8:01 a.m.Jim Oravetz-8/5/2005
326Vion Initiates Phase I/II Trial Of CLORETAZINE(TM) (VNP40101M) In Chronic LymphoJim Oravetz-7/26/2005
325Vion Pharma 1Q Losses 7c/Shr Vs 7c DOW JONES NEWSWIRES May 3, 2005 8:01 a.m. AnJim Oravetz-5/3/2005
324Wells Fargo Starts Vion Pharma At Buy DOW JONES NEWSWIRES April 28, 2005 7:38 a.Jim Oravetz-4/28/2005
323BARRONS:: Wanted: Risk Takers April 2 Little biotechs were supposed to have beeJim Oravetz-4/4/2005
322Vion Reports Initial Data From Phase II Clinical Trial Of CLORETAZINE(TM) (VNP40Jim Oravetz-3/21/2005
321Vion Agrees With FDA On Phase III Trial Of Cloretazine DOW JONES NEWSWIRES FebrJim Oravetz-2/10/2005
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News